HMGN2P15: A Drug Target / Disease Biomarker (G100288165)

Target Name: HMGN2P15

NCBI ID: G100288165

HMGN2P15

Other Name(s): high mobility group nucleosomal binding domain 2 pseudogene 15 | High mobility group nucleosomal binding domain 2 pseudogene 15

HMGN2P15: A Drug Target / Disease Biomarker

HMGN2P15 is a protein that is expressed in various tissues of the body, including the brain, lungs, heart, kidneys, and intestines. It is a member of the homeobox gene family, which is a family of genes that are involved in the development and maintenance of tissues and organs. HMGN2P15 is unique among its family members because of its highly acidic amino acid residues, which are highly reactive and can easily undergoBase-dependent structural changes.

One of the defining features of HMGN2P15 is its ability to undergo conformational changes. This is important for the protein's function because it allows it to interact with a wide range of molecules, including small molecules, ions, and other proteins. In addition, HMGN2P15's acidic amino acid residues make it a good candidate for targeting by small molecules, which can alter the structure and function of the protein.

Another important feature of HMGN2P15 is its expression pattern. It is highly expressed in the brain, where it is involved in the development and maintenance of neural circuits. It is also expressed in other tissues, including the lungs, heart, kidneys, and intestines, where it is involved in the regulation of various physiological processes. This broad expression pattern makes it a potential drug target, as drugs that target this protein could have a wide range of therapeutic applications.

In addition to its expression and structural features, HMGN2P15 is also known for its role in various signaling pathways. It is a positive regulator of the Wnt signaling pathway, which is involved in the development and maintenance of tissues and organs. This means that when Wnt signaling is activated, HMGN2P15 is recruited to the cell surface, where it can interact with its downstream targets, such as the protein Fz-1.

Fz-1 is a transcription factor that is involved in the regulation of gene expression. It is a key regulator of the Wnt signaling pathway, and it is thought to play a role in the development and maintenance of various tissues, including the brain. By interacting with HMGN2P15, Fz-1 can influence the structure and function of the protein, which in turn can affect the behavior of the cell.

The potential therapeutic applications of HMGN2P15 are vast and varied. As a drug target, it could be used to treat a wide range of diseases, including cancer, neurodegenerative diseases, and respiratory diseases. It could also be used to validate new drug candidates, as well as to study the underlying mechanisms of its function.

In addition to its potential therapeutic applications, HMGN2P15 is also an important biomarker for several diseases. Its expression is often reduced in diseases, such as cancer, neurodegenerative diseases, and respiratory diseases. This could make it an attractive target for diagnostic tests, as well as for the development of new therapeutic strategies.

Overall, HMGN2P15 is a protein that is well-suited for study as a drug target or biomarker. Its unique structure, its ability to undergo conformational changes, and its expression pattern make it an attractive target for small molecules. Its role in the development and maintenance of tissues and organs, as well as its involvement in various signaling pathways, make it a valuable tool for the study of disease and the development of new therapeutic strategies.

Protein Name: High Mobility Group Nucleosomal Binding Domain 2 Pseudogene 15

The "HMGN2P15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HMGN2P15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets